Description: Histogen is a regenerative medicine company focused on developing patented, innovative technologies for aesthetic and therapeutic markets that replace and regenerate tissues in the body. The Company currently has three product candidates in clinical development intended to address what Histogen believes to be underserved, multi-billion dollar global markets: a treatment for hair loss, a dermal filler and a treatment for joint cartilage repair.
Home Page: www.histogen.com
HSTO Technical Analysis
10655 Sorrento Valley Road
San Diego,
CA
92121
United States
Phone:
858 526 3100
Officers
| Name | Title |
|---|---|
| Dr. Steven J. Mento Ph.D. | Exec. Chairman, Interim Pres & CEO |
| Ms. Susan A. Knudson | Exec. VP, CFO, Chief Compliance Officer & Corp. Sec. |
| Dr. Gail K. Naughton Ph.D. | Founder & Scientific Advisor |
| Mr. Stephen Hill Jr. | VP & Controller |
| Mr. Thomas L. Hubka | Director of Bus. Operations & Corp. Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2472 |
| Price-to-Sales TTM: | 1.1104 |
| IPO Date: | 2013-07-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 22 |